Article Text

Download PDFPDF
EP936 A feasibility study of gemcitabine and bevacizumab in women with platinum-resistant recurrent ovarian cancer
  1. S Nagao1,
  2. A Kogiku1,2,
  3. M Ota1,
  4. K Yamamoto1,
  5. M Narita1,
  6. K Shimada1,
  7. H Nagazawa1,
  8. T Shibutani1,
  9. K Yamamoto1,
  10. T Jimi1,
  11. H Yano1,
  12. M Kitai1,
  13. T Shiozaki1,
  14. K Matsuoka1 and
  15. S Yamaguchi1
  1. 1Gynecologic Oncology, Hyogo Cancer Center, Akashi
  2. 2Obstetrics and Gynecology, Nishi Kobe Medical Center, Kobe, Japan


Introduction/Background In the AURELIA trial, adding of bevacizumab to chemotherapy significantly improved response and survival without problematic toxicity in women with platinum-resistant ovarian cancer. However, information about bevacizumab in combination with gemcitabine is insufficient. We conducted a feasibility study to assess clinical activity and toxicity.

Methodology Women with platinum-resistant recurrent ovarian cancer who received one to three regimens of platinum-based chemotherapy were registered in this study. They received 15 mg/kg of bevacizumab intravenously on day 1 and gemcitabine 1000 mg/m2of gemcitabine intravenously on day 1 and 8 every 21 days to disease progression or unacceptable toxicity. The primary endpoint was completion rate of 3 cycles of chemotherapy. The secondary endpoints were clinical response rate, progression free survival,overall survival, and dose-limiting toxicity including bowel perforation, febrile neutropenia, and grade 4 thrombocytopenia. This study is registered with UMIN-CTR, number UMIN000016619.

Results Between April 1, 2015 and December 31, 2018, 19 patients were enrolled into this study. There were 12 high grade serous, 1 endometrial, 4 clear cell, and 2 other types of carcinoma. Eighteen of 19 (95%) received 3 or more, and 9 (47%) received 6 or more cycles of study treatment. Objective responses were observed in 8 of 19 patients (42% overall; complete response 16%, partial response 26%), with an additional 8 (42%) having stable disease. Hematologic toxicity was neutropenia grade 3/4 in 9 (47%), anemia grade 3/4 in 2 (11%), thrombocytopenia grade 3/4 in 1 (5%). Non-hematologic toxicity included grade 3 hypertension in 1 (5%), grade 3 protein urea in one (5%) and possibly-related grade 3 interstitial pneumonia in 1 (5%). No patient encountered dose-limiting toxicity. Median progression free survival was 5.1 months, and median overall survival was 21.3 months.

Conclusion Combination chemotherapy with gemcitabine and bevacizumab is feasible in women with platinum-resistant recurrent ovarian cancer.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.